FLD just reported the kind of print that makes analysts reach for the red pen.
Q1 2026 EPS came in at -$0.59 against a -$0.15 estimate. Revenue of $5.6 million missed the $10 million consensus by nearly half. Cantor Fitzgerald — the most active coverage voice on this name — responded the same morning by maintaining its Overweight rating but cutting its price target from $2.00 to $1.70. That puts the target barely above the $1.48 close, a far cry from the $6.50 target Cantor initiated with last July. HC Wainwright, the other active firm on the stock, slashed its target from $7.00 to $3.00 back in March. The mean target across covering analysts is $3.13, but given the trajectory of recent cuts — from $7, $6.50, $4.50 and now $3 and $1.70 — the headline average flatters a story in rapid revision. The one genuine bright spot in the factor picture: EPS surprise ranks at the 97th percentile historically, though with estimates now anchored this low, beating them is a lower bar.
Despite the miss, the stock held up remarkably well. FLD closed at $1.48 on May 12, up 15% on the week and 18% over the past month. That resilience in the face of a heavy earnings miss — and a secondary shelf filing for resale of up to 1.04 million shares announced just days before results — is the central tension this week. The stock has shed 43% year-to-date, but buyers clearly stepped in around current levels.
Borrow conditions give some context for that resilience. Short interest is light at just under 0.9% of float, well below any level that would constitute a meaningful squeeze setup. The lending pool has loosened this week: availability improved as cost-to-borrow eased to 21.3% from highs near 30% that persisted through most of April. That's a notable move — CTB has fallen roughly 19% over the past month — suggesting reduced urgency among short sellers at current levels. With the borrow market this relaxed, there is no structural short-side pressure underpinning the stock's resilience; the buying is coming from somewhere else.
Options positioning reinforces the bullish lean. The put/call ratio has dropped to 0.15, below its 20-day average of 0.17 and near the lower end of its recent range. That's a meaningfully call-heavy book — not unusual for a small-cap with a speculative following, but notable in the context of results week. The ORTEX short score of 47.4 has drifted lower through the past two weeks from a peak of 51.8 on May 1, consistent with a picture of bears backing off rather than pressing.
Ownership is concentrated in a way that complicates simple supply/demand reads. Fulgur Frontier Capital holds 27% of shares outstanding, with Emerald ESG Sponsor, Betsy Cohen, and founder/CEO Will Reeves collectively accounting for another 33%. With roughly 60% of the company in the hands of a handful of strategic or insider holders, the effective tradeable float is narrow. Reeves himself added 268,573 shares in the week ending May 4, even as he sold a modest 5,537 shares the same day — a routine tax-withholding-type pattern that follows restricted stock awards of over 12,000 shares. The net insider picture over 90 days is essentially flat in dollar terms, a small positive.
With Q2 results scheduled for May 19 — just one week out — the next test arrives quickly. The gap between analyst targets, still clustered $1.22 to $1.55 above the current price, and the underlying financials is what the market will be measuring against that print.
See the live data behind this article on ORTEX.
Open FLD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
